MALVERN, Pa., Jan. 23, 2026 (WORLD NEWSWIRE)– TELA Bio, Inc. (” TELA Bio”) (NASDAQ: TELA), a commercial-stage medical innovation business concentrated on supplying ingenious soft-tissue restoration services, today revealed that the Payment Committee of the Board of Directors of TELA Bio authorized incentive grants of limited stock systems covering 14,250 shares of its typical stock to 5 newly-hired workers, with a grant date of January 20, 2026 (the “Grant Date”). The limited stock systems were given pursuant to the Nasdaq Guideline 5635( c)( 4) incentive grant exception as a part of each person’s work settlement and were given as a temptation product to his/her approval of work with TELA Bio.
The limited stock systems will vest in equivalent yearly installations over 4 years, based on each person’s ongoing service with TELA Bio through the relevant vesting dates.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical innovation business concentrated on supplying ingenious innovations that enhance medical results by focusing on the conservation and remediation of the client’s own anatomy. The Business is devoted to supplying cosmetic surgeons with innovative, financially efficient soft-tissue restoration services that take advantage of the client’s natural recovery action while reducing long-lasting direct exposure to irreversible artificial products. To learn more, go to www.telabio.com
Care Relating To Positive Declarations
This news release consists of positive declarations within the significance of The Personal Securities Lawsuits Reform Act of 1995. Words such as “may,” “might,” “will,” “should,” “think,” “anticipate,” “expect,” “quote,” “continue,” “forecast,” “projection,” “job,” “strategy,” “mean” or comparable expressions, or declarations concerning intent, belief, or present expectations are positive declarations and show the present beliefs of TELA Bio’s management. These declarations are not assurances of future efficiency and go through specific threats, unpredictabilities and other aspects that might trigger real outcomes and occasions to vary materially and negatively from those shown by such positive declarations. These threats and unpredictabilities are explained more completely in the “Danger Aspects” area and in other places in our filings with the Securities and Exchange Commission and readily available at www.sec.gov, consisting of in our Yearly Report on Kind 10-K and Quarterly Reports on Kind 10-Q. Any positive declarations that we make in this statement speak just since the date of this news release, and TELA Bio presumes no commitment to upgrade positive declarations whether as an outcome of brand-new details, future occasions or otherwise after the date of this news release, other than as needed under relevant law.
Financier Contact
Louisa Smith
[email protected]